27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Analyst Elemer Piros noted that the company reported the initiation of its FAB-C Phase II study with ZYN002 in children with Fragile X Syndrome, enrolling about 16 patients and administering ZYN002 4.2 percent gel at doses from 50 mg daily titrated up to 125 mg BID for a period of six weeks. The analyst expects top-line data from the study late in the first half of 2017.
Cantor Fitzgerald believes a positive read out could provide additional upside to its estimates. ZYN002, a synthetic cannabidiol gel for treating neurologic conditions, is being investigated in three Phase 2 studies, with the upcoming studies expected to provide readout of clinical efficacy. The firm noted that the drug has successfully achieved desired levels of CBD concentration. Failure to reach statistical or clinical significance in one or more of these trails would significantly reduce the likelihood of approval, the firm added.
Cantor Fitzgerald reiterated its Overweight rating and $28 price target on the shares of the company.
At time of writing, Zynerba Pharma shares were rising 2.16 percent to $15.93.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.